bullish
Alteogen (196170 KS): First Proprietary Product Approval in Korea To Improve Revenue Visibility
632 Views05 Jan 2024 09:30
SUMMARY
- Alteogen Inc (196170 KS)'s first proprietary recombinant human hyaluronidase liquid product, Tergase (ALT-BB4) is currently under approval process in Korea and is expected to receive approval in early 2024.
- Tergase is a stand-alone hyaluronidase product that can be used for the treatment of various medical conditions, such as pain relief, edema treatment, and hyaluronic acid filler removal.
- Compared to commercially available animal-derived hyaluronidase products in the market, Tergase is a highly purified product of high-quality with very few impurities and an excellent side effect profile.
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
Rising
Tina Banerjee
Global Healthcare Analyst
Price Chart(Sign Up to Access)
- Alteogen (196170 KS): Transitioning Toward Becoming Commercial Stage Biotech Company11 Jul 2024
- Alteogen: Block Deal Sale of About 3% of Shares27 Mar 2024
- Alteogen (196170 KS): Modified License Agreement For Major Platform Technology Is A Hard Catalyst23 Feb 2024
- KRX New Deal Index Rebalance Preview: Changes with Flow & Impact04 Jan 2024
- Alteogen (196170 KS): Milestone Payments and Pipeline Progress Strengthen Business Growth Prospect19 Jun 2023
- Alteogen (196170 KS): Distinct Platform Technology; Biosimilar Pipeline; Potential Value Unlocking10 Feb 2023
x